HC Wainwright Issues Pessimistic Forecast for AXSM Earnings

Key Points

• HC Wainwright lowered its Q3 2027 EPS forecast for Axsome Therapeutics to $1.84 from $1.92, while maintaining a Buy rating. It estimates FY2027 EPS of $4.80.
• Axsome’s latest quarter beat analyst expectations, reporting a loss of $0.25 per share versus the forecast loss of $0.63, and revenue of $259.69 million, up 51.9% year over year.
• Analyst sentiment remains broadly positive: the stock has a Moderate Buy consensus rating and an average price target of $267.58, although several firms recently lowered their targets.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2027 earnings estimates for shares of Axsome Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $1.84 per share for the quarter, down from their previous estimate of $1.92. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Axsome Therapeutics' Q4 2027 earnings at $2.52 EPS and FY2027 earnings at $4.80 EPS.

Several other equities analysts also recently weighed in on the stock. Guggenheim cut their price target on shares of Axsome Therapeutics from $275.00 to $250.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. BMO Capital Markets started coverage on shares of Axsome Therapeutics in a research note on Monday, July 20th. They set an "outperform" rating and a $310.00 price objective for the company. Royal Bank Of Canada dropped their price objective on shares of Axsome Therapeutics from $295.00 to $273.00 and set an "outperform" rating on the stock in a report on Tuesday, November 3rd. Piper Sandler dropped their price objective on shares of Axsome Therapeutics from $258.00 to $238.00 and set an "overweight" rating on the stock in a report on Monday, October 26th. Finally, Wells Fargo & Company reiterated an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $267.58.

Axsome Therapeutics Trading Up 1.2%

Axsome Therapeutics stock opened at $133.96 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21. Axsome Therapeutics has a 52 week low of $123.00 and a 52 week high of $260.19. The company has a market capitalization of $7.05 billion, a price-to-earnings ratio of -43.78 and a beta of 0.86. The stock has a 50-day moving average price of $176.31 and a 200 day moving average price of $197.60.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.38. The business had revenue of $259.69 million during the quarter, compared to analysts' expectations of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. The business's quarterly revenue was up 51.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.94) earnings per share.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of the business. Hollencrest Capital Management increased its position in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company's stock valued at $34,000 after buying an additional 160 shares in the last quarter. Jacobi Capital Management LLC purchased a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $47,000. ABS Direct Equity Fund LLC acquired a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $60,000. Silvant Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $66,000. Finally, GAMMA Investing LLC raised its holdings in shares of Axsome Therapeutics by 19.9% during the third quarter. GAMMA Investing LLC now owns 416 shares of the company's stock valued at $77,000 after acquiring an additional 69 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Mark Jacobson sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the sale, the chief operating officer owned 10,000 shares of the company's stock, valued at $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 20.60% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau.

Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.